Lonza Group AG (FRA:LO3A)

Market Cap	41.70B
Revenue (ttm)	7.59B
Net Income (ttm)	784.82M
Shares Out	n/a
EPS (ttm)	11.10
PE Ratio	53.13
Forward PE	30.40
Dividend	0.27 (0.47%)
Ex-Dividend Date	May 14, 2025

Volume	142
Average Volume	7
Open	58.50
Previous Close	58.00
Day's Range	58.50 - 59.00
52-Week Range	50.00 - 65.00
Beta	n/a
RSI	64.27
Earnings Date	Jan 28, 2026

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substanc...

• Industry: Chemicals and Allied Products
• Founded: 1897
• Employees: 18,944
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LO3A

Financial Performance

In 2024, Lonza Group AG's revenue was 6.57 billion, a decrease of -2.13% compared to the previous year's 6.72 billion. Earnings were 636.00 million, a decrease of -2.75%.

Financial numbers in CHF